LYCOS RETRIEVER 
Provera: Woman
built 623 days ago
Depo-Provera has been determined to be 99.7% effective in preventing conception. Progestins do not protect a woman from sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS). The use of latex (rubber) condoms or abstinence is recommended for protection from these diseases. See "Side Effects" for additional precautionary information.
Source:
Depo Provera is a man-made hormone like the hormone progesterone, which is normally made by a woman's body. After you have received Depo Provera, the hormone effects last for about 12 weeks. Depo Provera works by keeping eggs from being released from the ovaries, and by making the mucus from the cervix (the opening into the uterus) thick, so that it is hard for sperm to get through it.
Source:
Depo-Provera CI should be used as a long-term birth control method (e.g. longer than 2 years) only if other birth control methods are inadequate. BMD should be evaluated when a woman needs to continue to use Depo-Provera CI long term. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity.
Source:
Depo-Provera can be given to a woman who has just had a baby and to women who are breastfeeding. Studies regarding the effect of Depo Provera on breast milk show either no change or a possible increase in the volume of breast milk compared to birth control pill users and women using no contraception.
Source:
Depo-Provera is an injectable progestin-only prescription method of reversible birth control. It contains a hormone that is similar to the progesterone made by a woman's ovaries to regulate the menstrual cycle. Depo-Provera stops the ovaries from releasing an egg (ovulation), thickens cervical mucus to prevent sperm from combining with the egg and changes the uterine lining, which, in theory, may prevent implantation of a fertilized egg.
Source:
Most sources cite the failure rate for Depo-Provera at 0.3 percent annually, which would be three women out of a thousand per year. This number is based on large prospective clinical trials of women actually using Depo-Provera. Another method of determining efficacy is based on retrospective surveys that rely on a woman's recall of her contraceptive use over the past 4 to 5 years, such as the National Surveys of Family Growth (NSFG) -- a primary source of data used for estimating user-dependent contraceptive failure rates in the United States. The number of women in the NSFG retrospective survey using Depo-Provera, Norplant, and IUDs is small, much smaller then number of women in the prospective clinical trials that evaluated the effectiveness of Depo-Provera, Norplant, and IUDs. NSFG survey data may uncover more realistic failure rates for user-dependent contraceptive methods, but has been found to produce unrealistically high failure rates for contraceptive methods that are not user-dependent (this has been attributed to contraceptive overreporting). For example, NSFG survey data combined from 1988 and 1995 for Depo-Provera, Norplant, and IUDs produced a combined standardized failure rate for these three methods of 3.2 per year.
Source:
MORE ABOUT
Woman